| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2008-09-25 13:34:38 UTC |
|---|
| Update Date | 2022-03-07 02:51:00 UTC |
|---|
| HMDB ID | HMDB0010622 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | PG(18:1(11Z)/18:3(9Z,12Z,15Z)) |
|---|
| Description | PG(18:1(11Z)/18:3(9Z,12Z,15Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:1(11Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of a-linolenic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phosphatidylglycerol is present at a level of 1-2% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1'-sn-glycerol 3'-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. |
|---|
| Structure | [H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCCCCCCCC\C=C/CCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC InChI=1S/C42H75O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h6,8,12-15,18,20,39-40,43-44H,3-5,7,9-11,16-17,19,21-38H2,1-2H3,(H,47,48)/b8-6-,14-12-,15-13-,20-18-/t39-,40+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 1-(11Z-Octadecenoyl)-2-(9Z,12Z,15Z-octadeatrienoyl)-sn-glycero-3-phospho-(1'-glycerol) | HMDB | | 1-Vaccenoyl-2-a-linolenoyl-sn-glycero-3-phosphoglycerol | HMDB | | 1-Vaccenoyl-2-alpha-linolenoyl-sn-glycero-3-phosphoglycerol | HMDB | | GPG(18:1/18:3) | HMDB | | GPG(18:1N7/18:3N3) | HMDB | | GPG(18:1W7/18:3W3) | HMDB | | GPG(36:4) | HMDB | | PG(18:1/18:3) | HMDB | | PG(18:1N7/18:3N3) | HMDB | | PG(18:1W7/18:3W3) | HMDB | | PG(36:4) | HMDB | | Phosphatidylglycerol(18:1/18:3) | HMDB | | Phosphatidylglycerol(18:1n7/18:3n3) | HMDB | | Phosphatidylglycerol(18:1W7/18:3W3) | HMDB | | Phosphatidylglycerol(36:4) | HMDB | | 1-(11Z-Octadecenoyl)-2-(9Z,12Z,15Z-octadeatrienoyl)-sn-glycero-3-phosphoglycerol | HMDB | | PG(18:1(11Z)/18:3(9Z,12Z,15Z)) | Lipid Annotator |
|
|---|
| Chemical Formula | C42H75O10P |
|---|
| Average Molecular Weight | 771.0127 |
|---|
| Monoisotopic Molecular Weight | 770.509785132 |
|---|
| IUPAC Name | [(2S)-2,3-dihydroxypropoxy][(2R)-3-[(11Z)-octadec-11-enoyloxy]-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]propoxy]phosphinic acid |
|---|
| Traditional Name | (2S)-2,3-dihydroxypropoxy(2R)-3-[(11Z)-octadec-11-enoyloxy]-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]propoxyphosphinic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCCCCCCCC\C=C/CCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC |
|---|
| InChI Identifier | InChI=1S/C42H75O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h6,8,12-15,18,20,39-40,43-44H,3-5,7,9-11,16-17,19,21-38H2,1-2H3,(H,47,48)/b8-6-,14-12-,15-13-,20-18-/t39-,40+/m0/s1 |
|---|
| InChI Key | QUMYVZXTAFJZPC-KEXKQFALSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phosphatidylglycerols. These are glycerophosphoglycerols in which two fatty acids are bonded to the 1-glycerol moiety through ester linkages. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Glycerophospholipids |
|---|
| Sub Class | Glycerophosphoglycerols |
|---|
| Direct Parent | Phosphatidylglycerols |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,2-diacylglycerophosphoglycerol
- Fatty acid ester
- Dialkyl phosphate
- Dicarboxylic acid or derivatives
- Organic phosphoric acid derivative
- Phosphoric acid ester
- Alkyl phosphate
- Fatty acyl
- 1,2-diol
- Carboxylic acid ester
- Secondary alcohol
- Carboxylic acid derivative
- Organic oxide
- Organooxygen compound
- Alcohol
- Organic oxygen compound
- Primary alcohol
- Carbonyl group
- Hydrocarbon derivative
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Naturally occurring processBiological processBiochemical pathwayMetabolic pathway- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:0) (PathBank: SMP0099638)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z)/20:1(11Z)) (PathBank: SMP0099644)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z)/22:0) (PathBank: SMP0099647)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z)/22:1(13Z)) (PathBank: SMP0099648)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/22:0/22:1(13Z)) (PathBank: SMP0099657)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:0) (PathBank: SMP0099636)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0099640)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099641)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/22:1(13Z)/22:1(13Z)) (PathBank: SMP0099658)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)) (PathBank: SMP0085168)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:1(13Z)) (PathBank: SMP0099637)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:1(11Z)) (PathBank: SMP0099639)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/22:0/22:0) (PathBank: SMP0099656)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:0) (PathBank: SMP0085169)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:1(11Z)) (PathBank: SMP0099633)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0099634)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099635)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/22:0) (PathBank: SMP0099642)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/22:1(13Z)) (PathBank: SMP0099643)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0099649)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099650)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099653)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:1(13Z)) (PathBank: SMP0081849)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:1(13Z)) (PathBank: SMP0081854)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z)/20:1(13Z)) (PathBank: SMP0081858)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(13Z)/20:1(13Z)) (PathBank: SMP0081861)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(13Z)/22:0) (PathBank: SMP0081862)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(13Z)/22:1(13Z)) (PathBank: SMP0081863)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)) (PathBank: SMP0085170)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)) (PathBank: SMP0085171)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0085174)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:3(5Z,8Z,11Z)) (PathBank: SMP0085176)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:3(8Z,11Z,14Z)) (PathBank: SMP0085177)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0085180)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:3(5Z,8Z,11Z)) (PathBank: SMP0085181)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:3(8Z,11Z,14Z)) (PathBank: SMP0085182)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0085183)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0085184)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0085185)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)/20:3(8Z,11Z,14Z)) (PathBank: SMP0085186)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0085187)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0085188)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0085189)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0085192)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0085194)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) (PathBank: SMP0085195)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z)/20:4(5Z,8Z,11Z,14Z)) (PathBank: SMP0099645)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z)) (PathBank: SMP0099646)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/22:0) (PathBank: SMP0099651)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/22:1(13Z)) (PathBank: SMP0099652)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/22:0) (PathBank: SMP0099654)
- Cardiolipin Biosynthesis CL(18:1(11Z)/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/22:1(13Z)) (PathBank: SMP0099655)
|
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 7.73 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 30.569 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.96 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 77.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 5498.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 287.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 319.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 217.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1121.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1725.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1098.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 227.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 3200.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 1165.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2807.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 1254.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 719.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 292.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 584.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 10.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-18 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 10V, Positive-QTOF | splash10-0hvl-4091721700-476141bc2afc6e2496f8 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 20V, Positive-QTOF | splash10-0hk9-5192422200-ca4dfcee04e88b1b1a36 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 40V, Positive-QTOF | splash10-0adr-9065420000-641f11dc9558ddb3f9c3 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 10V, Negative-QTOF | splash10-02cr-0190100200-30a74687102b24b5fc03 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 20V, Negative-QTOF | splash10-01si-5290200000-4d968e987a887d41aec9 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 40V, Negative-QTOF | splash10-004i-9020000000-2e84df79c65aec129d7a | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 10V, Negative-QTOF | splash10-014i-0000000900-c28bac06e088565afc8a | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 20V, Negative-QTOF | splash10-017i-0090310400-f55cd4632b5316fab73b | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - PG(18:1(11Z)/18:3(9Z,12Z,15Z)) 40V, Negative-QTOF | splash10-017i-0190310400-0b48fc7bf8546f2466ba | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|